Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" ...

President Trump has nominated Pierre Gentin, chief legal officer of the consulting giant McKinsey & Co. since 2019, to serve ...

A U.S. Senate committee voted on Wednesday to advance President Donald Trump's nominee Howard Lutnick, billionaire chairman ...

Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...

Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC has several regulatory decisions this year ...

Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that ...

As previously reported last night, Cantor Fitzgerald initiated coverage of five Government Technology & Space, or “GovTech,” stocks, starting SAIC (SAIC) with a Neutral rating and $120 price ...

As previously reported last night, Cantor Fitzgerald analyst Colin Canfield initiated coverage of five Government Technology & Space, or “GovTech,” stocks, starting SAIC (SAIC) with a Neutral ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Surgery Partners (NASDAQ:SGRY) with a steady price target of $36.00. The stock, which has shown significant momentum with a 20% ...

On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Cipher Mining shares (NASDAQ:CIFR), with a set price target of $11.00. The firm's analyst, Brett Knoblauch, provided insight into ...

Cantor Fitzgerald lowered the firm’s price target on Cigna (CI) to $350 from $400 and keeps an Overweight rating on the shares. Cantor is confident that Cigna can correct their stop-loss pricing ...